CLLS vs. ZURA, MOLN, DBVT, AGEN, VXRT, OMGA, SCLX, VCXB, CRDL, and GNFT
Should you be buying Cellectis stock or one of its competitors? The main competitors of Cellectis include Zura Bio (ZURA), Molecular Partners (MOLN), DBV Technologies (DBVT), Agenus (AGEN), Vaxart (VXRT), Omega Therapeutics (OMGA), Scilex (SCLX), 10X Capital Venture Acquisition Corp. III (VCXB), Cardiol Therapeutics (CRDL), and Genfit (GNFT). These companies are all part of the "biological products, except diagnostic" industry.
Cellectis (NASDAQ:CLLS) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, community ranking, valuation, dividends, risk and institutional ownership.
Zura Bio has a net margin of 0.00% compared to Cellectis' net margin of -346.65%. Cellectis' return on equity of -73.03% beat Zura Bio's return on equity.
Cellectis presently has a consensus target price of $8.50, indicating a potential upside of 238.65%. Zura Bio has a consensus target price of $16.40, indicating a potential upside of 271.88%. Given Zura Bio's stronger consensus rating and higher probable upside, analysts clearly believe Zura Bio is more favorable than Cellectis.
In the previous week, Zura Bio had 11 more articles in the media than Cellectis. MarketBeat recorded 14 mentions for Zura Bio and 3 mentions for Cellectis. Zura Bio's average media sentiment score of 0.98 beat Cellectis' score of -0.22 indicating that Zura Bio is being referred to more favorably in the news media.
Zura Bio has lower revenue, but higher earnings than Cellectis.
Cellectis received 395 more outperform votes than Zura Bio when rated by MarketBeat users. However, 100.00% of users gave Zura Bio an outperform vote while only 68.36% of users gave Cellectis an outperform vote.
Cellectis has a beta of 3.12, suggesting that its stock price is 212% more volatile than the S&P 500. Comparatively, Zura Bio has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.
63.9% of Cellectis shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Comparatively, 15.8% of Zura Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Zura Bio beats Cellectis on 9 of the 16 factors compared between the two stocks.
Get Cellectis News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cellectis Competitors List
Related Companies and Tools
